108 related articles for article (PubMed ID: 23131342)
1. Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat.
Hunt HJ; Ray NC; Hynd G; Sutton J; Sajad M; O'Connor E; Ahmed S; Lockey P; Daly S; Buckley G; Clark RD; Roe R; Blasey C; Belanoff J
Bioorg Med Chem Lett; 2012 Dec; 22(24):7376-80. PubMed ID: 23131342
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.
Beebe KL; Block T; Debattista C; Blasey C; Belanoff JK
Behav Brain Res; 2006 Aug; 171(2):225-9. PubMed ID: 16782211
[TBL] [Abstract][Full Text] [Related]
3. Discovery of liver selective non-steroidal glucocorticoid receptor antagonist as novel antidiabetic agents.
Shah K; Patel D; Jadav P; Sheikh M; Sairam KV; Joharapurkar A; Jain MR; Bahekar R
Bioorg Med Chem Lett; 2012 Sep; 22(18):5857-62. PubMed ID: 22917520
[TBL] [Abstract][Full Text] [Related]
4. Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.
Belanoff JK; Blasey CM; Clark RD; Roe RL
Eur J Pharmacol; 2011 Mar; 655(1-3):117-20. PubMed ID: 21269600
[TBL] [Abstract][Full Text] [Related]
5. Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.
Belanoff JK; Blasey CM; Clark RD; Roe RL
Diabetes Obes Metab; 2010 Jun; 12(6):545-7. PubMed ID: 20518810
[TBL] [Abstract][Full Text] [Related]
6. Effects of combined glucocorticoid/mineralocorticoid receptor modulation (CORT118335) on energy balance, adiposity, and lipid metabolism in male rats.
Nguyen ET; Berman S; Streicher J; Estrada CM; Caldwell JL; Ghisays V; Ulrich-Lai Y; Solomon MB
Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E337-E349. PubMed ID: 31112405
[TBL] [Abstract][Full Text] [Related]
7. LLY-2707, a novel nonsteroidal glucocorticoid antagonist that reduces atypical antipsychotic-associated weight gain in rats.
Sindelar DK; Carson MW; Morin M; Shaw J; Barr RJ; Need A; Alexander-Chacko J; Coghlan M; Gehlert DR
J Pharmacol Exp Ther; 2014 Jan; 348(1):192-201. PubMed ID: 24163440
[TBL] [Abstract][Full Text] [Related]
8. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain.
Patil BM; Kulkarni NM; Unger BS
Eur J Pharmacol; 2006 Dec; 551(1-3):112-5. PubMed ID: 17046744
[TBL] [Abstract][Full Text] [Related]
9. The discovery of potent and selective non-steroidal glucocorticoid receptor modulators, suitable for inhalation.
Edman K; Ahlgren R; Bengtsson M; Bladh H; Bäckström S; Dahmén J; Henriksson K; Hillertz P; Hulikal V; Jerre A; Kinchin L; Kåse C; Lepistö M; Mile I; Nilsson S; Smailagic A; Taylor J; Tjörnebo A; Wissler L; Hansson T
Bioorg Med Chem Lett; 2014 Jun; 24(11):2571-7. PubMed ID: 24755427
[TBL] [Abstract][Full Text] [Related]
10. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.
Shobo M; Yamada H; Mihara T; Kondo Y; Irie M; Harada K; Ni K; Matsuoka N; Kayama Y
Behav Brain Res; 2011 Jan; 216(2):561-8. PubMed ID: 20816897
[TBL] [Abstract][Full Text] [Related]
11. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.
Deng C; Lian J; Pai N; Huang XF
J Psychopharmacol; 2012 Sep; 26(9):1271-9. PubMed ID: 22695490
[TBL] [Abstract][Full Text] [Related]
12. Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study.
Hunt HJ; Donaldson K; Strem M; Tudor IC; Sweet-Smith S; Sidhu S
J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):632-637. PubMed ID: 34369902
[TBL] [Abstract][Full Text] [Related]
13. The role of thermogenesis in antipsychotic drug-induced weight gain.
Stefanidis A; Verty AN; Allen AM; Owens NC; Cowley MA; Oldfield BJ
Obesity (Silver Spring); 2009 Jan; 17(1):16-24. PubMed ID: 19107124
[TBL] [Abstract][Full Text] [Related]
14. Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist.
Brown AR; Bosies M; Cameron H; Clark J; Cowley A; Craighead M; Elmore MA; Firth A; Goodwin R; Goutcher S; Grant E; Grassie M; Grove SJ; Hamilton NM; Hampson H; Hillier A; Ho KK; Kiczun M; Kingsbury C; Kultgen SG; Littlewood PT; Lusher SJ; Macdonald S; McIntosh L; McIntyre T; Mistry A; Morphy JR; Nimz O; Ohlmeyer M; Pick J; Rankovic Z; Sherborne B; Smith A; Speake M; Spinks G; Thomson F; Watson L; Weston M
Bioorg Med Chem Lett; 2011 Jan; 21(1):137-40. PubMed ID: 21129964
[TBL] [Abstract][Full Text] [Related]
15. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.
Cooper GD; Harrold JA; Halford JC; Goudie AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):428-36. PubMed ID: 17933447
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.
Choi S; DiSilvio B; Unangst J; Fernstrom JD
Life Sci; 2007 Sep; 81(12):1024-30. PubMed ID: 17822717
[TBL] [Abstract][Full Text] [Related]
17. Discovery of orally available tetrahydroquinoline-based glucocorticoid receptor agonists.
Hudson AR; Higuchi RI; Roach SL; Adams ME; Vassar A; Syka PM; Mais DE; Miner JN; Marschke KB; Zhi L
Bioorg Med Chem Lett; 2011 Mar; 21(6):1697-700. PubMed ID: 21316964
[TBL] [Abstract][Full Text] [Related]
18. Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.
Failli AA; Shumsky JS; Steffan RJ; Caggiano TJ; Williams DK; Trybulski EJ; Ning X; Lock Y; Tanikella T; Hartmann D; Chan PS; Park CH
Bioorg Med Chem Lett; 2006 Feb; 16(4):954-9. PubMed ID: 16297621
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent and dissociated non-steroidal glucocorticoid receptor agonist containing an alkyl carbinol pharmacophore.
Razavi H; Riether D; Harcken C; Bentzien J; Dinallo RM; Souza D; Nelson RM; Kukulka A; Fadra-Khan TN; Pack EJ; Zuvela-Jelaska L; Pelletier J; Panzenbeck M; Torcellini CA; Proudfoot JR; Nabozny GH; Thomson DS
Bioorg Med Chem Lett; 2014 Apr; 24(8):1934-40. PubMed ID: 24656565
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.
van der Zwaal EM; Luijendijk MC; Adan RA; la Fleur SE
Eur J Pharmacol; 2008 May; 585(1):130-6. PubMed ID: 18378227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
